Logo do repositório
 
Publicação

Comments on the discordant recommendations for the use of symptomatic slow-acting drugs in knee osteoarthritis

2015-05-01Recensão Acesso aberto
Ver registo simples
dc.contributor.authorReginster, Jean Yves
dc.contributor.authorCooper, Cyrus
dc.contributor.authorHochberg, Marc
dc.contributor.authorPelletier, Jean Pierre
dc.contributor.authorRizzoli, René
dc.contributor.authorKanis, John
dc.contributor.authorAbadie, Eric
dc.contributor.authorMaheu, Emmanuel
dc.contributor.authorBrandi, Maria Luisa
dc.contributor.authorDevogelaer, Jean Pierre
dc.contributor.authorBranco, Jaime
dc.contributor.authorBranco, Jaime
dc.contributor.authorHerrero-Beaumont, Gabriel
dc.contributor.authorD'Hooghe, Pieter
dc.contributor.authorBruyère, Olivier
dc.contributor.institutionNOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)
dc.contributor.institutionCentro de Estudos de Doenças Crónicas (CEDOC)
dc.contributor.pblInforma Healthcare
dc.date.accessioned2022-07-22T22:20:07Z
dc.date.available2022-07-24T00:31:42Z
dc.date.embargoedUntil2022-07-23
dc.date.issued2015-05-01
dc.description.abstractDespite the near concurrent publication by influential scientific organizations, there are important differences in interpretation of the evidence base and the conclusions derived from the recent Osteoarthritis Research Society International (OARSI) guidelines for the management of knee osteoarthritis, the American College of Rheumatology (ACR) guidelines (concerning also hip and hand osteoarthritis) and the algorithm recommendations by the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). This is particularly evident for the drug class of symptomatic slow-acting drugs in osteoarthritis. In this paper, we highlight these differences and try to understand where they derive from, proposing an evidence-based interpretation.en
dc.description.versionpublishersversion
dc.description.versionpublished
dc.format.extent5
dc.format.extent464182
dc.identifier.doi10.1185/03007995.2015.1027183
dc.identifier.issn0300-7995
dc.identifier.otherPURE: 3127136
dc.identifier.otherPURE UUID: 05e7b1c0-b95c-4eef-9f7e-b3b08d06372f
dc.identifier.otherScopus: 84928177249
dc.identifier.otherPubMed: 25753599
dc.identifier.otherWOS: 000353162900022
dc.identifier.urihttp://hdl.handle.net/10362/142323
dc.identifier.urlhttps://www.scopus.com/pages/publications/84928177249
dc.language.isoeng
dc.peerreviewedyes
dc.subjectChondroitin
dc.subjectGlucosamine
dc.subjectHyaluronic acid
dc.subjectOsteoarthritis
dc.subjectSymptomatic slow-acting drugs in osteoarthritis
dc.subjectGeneral Medicine
dc.titleComments on the discordant recommendations for the use of symptomatic slow-acting drugs in knee osteoarthritisen
dc.typereview
degois.publication.firstPage1041
degois.publication.issue5
degois.publication.lastPage1045
degois.publication.titleCurrent Medical Research and Opinion
degois.publication.volume31
dspace.entity.typePublication
person.familyNameBranco
person.givenNameJaime
person.identifier.ciencia-idB612-E5C3-60DC
person.identifier.orcid0000-0001-7024-4375
person.identifier.scopus-author-id8417815400
rcaap.rightsopenAccess
relation.isAuthorOfPublication4caea9f3-40dd-4c95-98ec-0120509287c0
relation.isAuthorOfPublication.latestForDiscovery4caea9f3-40dd-4c95-98ec-0120509287c0

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura
Nome:
Comments_on_the_discordant_recommendations_for_the_use_of_symptomatic_slow_acting_drugs_in_knee_osteoarthritis.pdf
Tamanho:
453.3 KB
Formato:
Adobe Portable Document Format
Ver/Abrir

Coleções

NMS: CEDOC - Artigos em revista internacional com arbitragem científica